Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Narumi Nakagiri's Stock Ratings
Daiwa Capital Analyst
Narumi Nakagiri is an analyst at Daiwa Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/08/2025
Overall Average Return
-15.9%
Smart Score
Overall Average Return Percentile
15th
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 08/16/2024 | ILMN | Buy Now | Illumina | $76.35 | 101.7% | Narumi Nakagiri23% | $120 → $154 | Upgrade | Neutral → Buy | Get Alert |
| 08/08/2024 | PFE | Buy Now | Pfizer | $22.86 | 48.73% | Narumi Nakagiri23% | $28 → $34 | Upgrade | Neutral → Outperform | Get Alert |
| 07/23/2024 | JNJ | Buy Now | Johnson & Johnson | $155.94 | -3.81% | Narumi Nakagiri23% | $160 → $150 | Downgrade | Outperform → Neutral | Get Alert |
| 12/21/2023 | AMGN | Buy Now | Amgen | $269.56 | 18.71% | Narumi Nakagiri23% | → $320 | Upgrade | Neutral → Buy | Get Alert |
| 11/02/2023 | BMY | Buy Now | Bristol-Myers Squibb | $46.99 | 14.92% | Narumi Nakagiri23% | $68 → $54 | Downgrade | Outperform → Neutral | Get Alert |
| 05/11/2023 | PFE | Buy Now | Pfizer | $22.86 | 66.23% | Narumi Nakagiri23% | $51 → $38 | Downgrade | Outperform → Neutral | Get Alert |
| 02/07/2023 | PFE | Buy Now | Pfizer | $22.86 | 123.1% | Narumi Nakagiri23% | → $51 | Upgrade | Neutral → Outperform | Get Alert |
| 07/07/2022 | MRK | Buy Now | Merck & Co | $78.44 | 30.04% | Narumi Nakagiri23% | $89 → $102 | Upgrade | Hold → Outperform | Get Alert |
| 12/16/2021 | MRK | Buy Now | Merck & Co | $78.44 | -10.76% | Narumi Nakagiri23% | → $70 | Initiates | → Neutral | Get Alert |
| 09/23/2021 | AMGN | Buy Now | Amgen | $269.56 | -18.39% | Narumi Nakagiri23% | → $220 | Downgrade | Outperform → Neutral | Get Alert |
